Our CEO's strong IT background and a corporate belief that technology must drive execution inspired Tower to develop an extremely sophisticated technology — the Tower MSP Automation Suite — to manage every aspect of our proactive business processes. The suite consolidates our more than 50 years of compliance expertise into the latest, proven technologies.
Tower's fully integrated MSP Automation Suite identifies barriers to settlement and prompts resolutions as it tracks each claim from intake to closure and provides end-to-end visibility into the claim's progress. We proactively intervene to address unnecessary medical costs and inappropriate drug usage and obtain the evidence needed for CMS approval before preparing the MSA.
We are the only company in our industry with a single point of contact through every step in the process. We remain involved until the closure of your claim and pride ourselves making the process easy for our clients. We are with you every step of the way.
A worker diagnosed with PTSD, anxiety and mood disorders received a regimen of psychotropic medications over the years. When the employer started to consider settlement, the initial MSA allocation was $1,687,081 — $30,058.44 for future medicals and $1,657,022 for pharmacy.
Tower identified the use of brand name medications, including Wellbutrin, Klonopin, Rozerem, and Neurontin as the key cost driver and recommended working with the claimant attorney and treating physician to switch brands to generics. When the conversion was completed, a physician’s statement was obtained confirming the switch from brand to generic as well as an updated prescription history documenting ongoing generic use.
With the physician’s statement properly documented, Tower submitted an MSA with an allocation of $112,572. CMS approved the MSA within eight days, allowing the parties to settle and saving the employer more than $1.5 million in unnecessary pharmacy costs.
Tower immediately identified the use of high cost brand name medication in the MSA and helped implement a plan to move the claimant to generics. While the brand-to-generic switch took several months to complete, each drug change reduced ongoing costs to the claim and ultimately produced over $1.5 million in savings on the MSA allocation.
MSA Cost Savings from Clinical Intervention
Average Conditional Payments Savings
Pre-Validation Checks
Conditional Payments Reduced to $0
Your source for industry leading insight & information
Lead, Not Follow Approach Yields Compliant & Cost-Effective MSAs
Just like all of us, CMS makes occasional errors. Believe it or not, the ...
On April 24, Tower MSA Partners CEO Rita Wilson and Chief Compliance ...
U.S. Attorney Again Takes on Plaintiff’s Attorney for Failure to Reimburse Medicare
On March 18, 2019 the U.S. Attorney for the District of Maryland announced ...
In a March 13, 2019 webinar, CMS provided a high-level overview of the ...
CMS to Hold Webinar on Electronic Payment Enhancement to MSPRP
CMS recently announced it will hold a webinar on March 13, 2019 at 1:00 PM ...
Medicare Secondary Payer policies and processes are always in flux, whether ...